PureVision Contact Lenses
Navigation Links
PureVision Contact Lenses
| Products | PureVision Contact Lenses |
| Company | Bausch & Lomb, Inc. |
| Item | PureVision Contact Lenses |
| Features |
|
| Description | Upgrade your hydrogel contact lens-wearing patients to Bausch & Lomb PureVision silicone hydrogel contact lenses with enhanced aspheric optical design. PureVision contact lenses deliver the ultimate technology in material and optical design to provide your patients with exceptional vision, health and comfort. |
| Info | Bausch & Lomb, Inc. Customer Service: 585-338-6000 Web site: http://www.bausch.com/en_US/ |
Related medicine products :
1. Refresh Contacts
2. Three-mirror Contact Lens 630
3. CT200 Contact Tonometer
4. CT100 Contact Tonometer
5. Contact Glass 901
6. One-mirror Contact Lens 902
7. One-mirror Contact Lens 902 S
8. Three-mirror Contact Lens 903
9. Three-mirror Contact Lens 903 S
10. One-mirror Contact Lens 904
11. Three-mirror Contact Lens 906
Breaking Medicine News(10 mins):Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight' 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3
[1] Winner Medical Reports Fourth Quarter and Fiscal 2009 Results[1] Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765[0] Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards [1] Wellness Cruise Offers Crystal Guests 'Indian Ocean Insight'[1] Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure
Other Medicine News:Health News:91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs 2Health News:91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs 3Health News:91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs 4Health News:91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs 5Health News:91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs 6Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Samarion(SM) Announces Formation of Outcome Based Study Team for Industry's Only Enterprise Quality Improvement System 2Health News:Samarion(SM) Announces Formation of Outcome Based Study Team for Industry's Only Enterprise Quality Improvement System 3Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 2Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 3Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 4Health News:Sonian Introduces the Most Affordable, Reliable and Scaleable Email Archiving Solution for All Messaging Systems 2Health News:MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2
91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAsStudy Challenges New Benchmark for High-Volume Heart Transplant HospitalsSamarion(SM) Announces Formation of Outcome Based Study Team for Industry's Only Enterprise Quality Improvement SystemOnmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality InitiativesSonian Introduces the Most Affordable, Reliable and Scaleable Email Archiving Solution for All Messaging SystemsMAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Rampant helper syndrome 9100 1Rampant helper syndrome 9100 2Virus resistant grapevines 9098 1Virus resistant grapevines 9098 2Ferns took to the trees and thrived 9095 1Ferns took to the trees and thrived 9095 2
[0] Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference[0] ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease[0] FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |